Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accounts Payables (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Accounts Payables data on record, last reported at $11.1 million in Q2 2025.

  • For Q2 2025, Accounts Payables rose 6.51% year-over-year to $11.1 million; the TTM value through Jun 2025 reached $11.1 million, up 6.51%, while the annual FY2024 figure was $10.7 million, 182.05% up from the prior year.
  • Accounts Payables reached $11.1 million in Q2 2025 per TNXP's latest filing, up from $4.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $11.1 million in Q2 2025 and bottomed at $3.8 million in Q4 2023.
  • Average Accounts Payables over 3 years is $7.1 million, with a median of $7.2 million recorded in 2023.
  • The widest YoY moves for Accounts Payables: up 182.05% in 2024, down 49.54% in 2024.
  • A 3-year view of Accounts Payables shows it stood at $3.8 million in 2023, then surged by 182.05% to $10.7 million in 2024, then grew by 3.9% to $11.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $11.1 million in Q2 2025, $4.2 million in Q1 2025, and $10.7 million in Q4 2024.